EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
News|Slideshows|July 15, 2020
AHA Guidelines on Obesity for CVD Prevention: 5 Questions
Author(s)Veronica Hackethal, MD
Obesity is a primary risk factor for cardiovascular disease and can also be modified with comprehensive care. Test yourself on the AHA/ACC recommendations for that care.
Advertisement
FOCUS: Preventive Cardiology and Obesity
Obesity is a risk factor for nearly all forms of cardiovascular and cardiometabolic disease. In fact, the epidemic status of obesity in the United States has been identified as responsible for the rise in deaths from heart disease after 4 decades of steady decline.
Prevention and management of overweight and obesity is central to primary prevention of CVD. Test yourself on the most r
Advertisement
Related to this article
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.
Semaglutide brought 40.4% of children below the obesity BMI threshold, according to top-line results from the phase 3 STEP Young clinical trial.
US clinicians increasingly prescribe GLP-1 drugs to young children with obesity, although overall use remains limited and access disparities persist.
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
Advertisement
Advertisement
Trending on Patient Care Online
1
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
2
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
3
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
4
What Is HIV PrEP and Who Needs It Most?
5